"10.1371_journal.pone.0061239","plos one","2013-04-19T00:00:00Z","Zachary Rosenes; Yee-Foong Mok; Shuo Yang; Michael D W Griffin; Terrence D Mulhern; Danny M Hatters; Frank Hensel; Geoffrey J Howlett","Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia; Patrys GmbH, Friedrich-Bergius-Ring 15, Würzburg, Germany","Conceived and designed the experiments: ZR YM MG TM DH GH. Performed the experiments: ZR YM SY. Analyzed the data: ZR YM SY MG TM DH GH. Contributed reagents/materials/analysis tools: FH ZR YM. Wrote the paper: TM DH GH.","This work is supported by an ARC linkage grant (LP100100392) and by Patrys Ltd, a company currently conducting clinical trials of PAT-SM6 as a potential anti-cancer treatment. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials. FH is the managing director of Patrys, GmbH. The PAT-SM6 antibody is proprietary to Patrys Limited and the company agrees to make to make freely available any materials and information described in their publication that may be reasonably requested for the purpose of academic, non-commercial research. Due to the proprietary nature of the antibody parties will need to enter into a material transfer agreement.","2013","04","Zachary Rosenes","ZR",8,TRUE,6,3,7,3,TRUE,TRUE,FALSE,0,NA,FALSE
